US equities
|
MU
$1,037.91
▼-4.60%
NVDA
$231.06
▼-2.70%
SNDK
$1,601.97
▼-5.34%
AMD
$618.18
▼-4.29%
INTC
$105.89
▼-6.39%
SPCX
$161.83
▼-3.44%
META
$717.66
▼-0.51%
PLTR
$196.05
▲+0.99%
MU
$1,037.91
▼-4.60%
NVDA
$231.06
▼-2.70%
SNDK
$1,601.97
▼-5.34%
AMD
$618.18
▼-4.29%
INTC
$105.89
▼-6.39%
SPCX
$161.83
▼-3.44%
META
$717.66
▼-0.51%
PLTR
$196.05
▲+0.99%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
NLS Pharmaceutics Ltd. - Ordinary Shares
(NQ:
NLSP
)
0.7620
UNCHANGED
Last Price
Updated: 4:00 PM EDT, Oct 30, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about NLS Pharmaceutics Ltd. - Ordinary Shares
< Previous
1
2
3
4
5
6
7
8
Next >
NLS Pharmaceutics Announces Preclinical Results Confirming the Potential Benefit and Safety Profile of NLS-4 for Circadian Rhythm Dysregulation and Chronic Fatigue Syndrome in Long-Covid Model
November 30, 2021
STANS, SWITZERLAND / ACCESSWIRE / November 30, 2021 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP, NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and...
From
NLS Pharmaceutics AG
Via
AccessWire
Topics
Intellectual Property
Regulatory Compliance
NLS Pharmaceutics CEO Issues Letter to Shareholders
November 01, 2021
STANS, SWITZERLAND / ACCESSWIRE / November 1, 2021 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the...
From
NLS Pharmaceutics AG
Via
AccessWire
Topics
Initial Public Offering
Intellectual Property
Regulatory Compliance
Leading the Charge to Develop the First Orexin-Targeted Therapy to Address Narcolepsy at its Root Cause
↗
October 20, 2021
Photo by MART PRODUCTION from Pexels The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial...
Via
Benzinga
NLS Pharmaceutics Announces Preclinical Data Demonstrating the Potential of NLS-4 (Lauflumide) to Treat Chronic Fatigue Associated With Long-COVID
October 14, 2021
STANS, SWITZERLAND / ACCESSWIRE / October 14, 2021 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP, NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and...
From
NLS Pharmaceutics AG
Via
AccessWire
Topics
Intellectual Property
Product Recall
Regulatory Compliance
36 of the Best Ideas Companies to Present at the Fall Harvest - Best Ideas from the Buy-Side Virtual Investor Conference on October 5th - 8th, 2021
October 04, 2021
RALEIGH, NC / ACCESSWIRE / October 4, 2021 / The Fall Harvest - Best Ideas from the Buy-Side will take place on October 5th - 8th, 2021, where 36 SmallCap, MicroCap and NanoCap public companies will be...
From
MicroCap Rodeo
Via
AccessWire
NLS Pharmaceutics to Participate in The Micro Cap Rodeo Fall Harvest Conference: Best Ideas from the Buy-side
September 30, 2021
STANS, SWITZERLAND / ACCESSWIRE / September 30, 2021 / NLS Pharmaceutics Ltd. (Nasdaq:NLSP, NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage pharmaceutical company focused on the discovery and...
From
NLS Pharmaceutics AG
Via
AccessWire
NLS Pharmaceutics Announces $20 Million Standby Equity Distribution Agreement and $2.5 Million Equity Investment
September 28, 2021
STANS, SWITZERLAND / ACCESSWIRE / September 28, 2021 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP, NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery...
From
NLS Pharmaceutics AG
Via
AccessWire
Topics
Intellectual Property
Regulatory Compliance
NLS Pharmaceutics to Participate in the Benzinga Healthcare Small Cap Conference
September 24, 2021
STANS, SWITZERLAND / ACCESSWIRE / September 24, 2021 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage pharmaceutical company focused on the...
From
NLS Pharmaceutics AG
Via
AccessWire
NLS Initiates Phase 2 Trial for Quilience in Narcolepsy and Announces First Patient Enrolled
September 14, 2021
STANS, SWITZERLAND / ACCESSWIRE / September 14, 2021 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage pharmaceutical company focused on the...
From
NLS Pharmaceutics AG
Via
AccessWire
Topics
Intellectual Property
Regulatory Compliance
NLS Pharmaceutics to Participate in the 23rd Annual H.C. Wainwright Global Investment Conference
September 08, 2021
STANS, SWITZERLAND / ACCESSWIRE / September 8, 2021 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage pharmaceutical company focused on the discovery...
From
NLS Pharmaceutics AG
Via
AccessWire
38 Stocks Moving In Friday's Mid-Day Session
↗
August 20, 2021
Gainers GeoVax Labs, Inc. (NASDAQ: GOVX) shares climbed 45.8% to $6.27 after the company presented data from ongoing studies of its preventive vaccine against COVID-19, showing...
Via
Benzinga
58 Biggest Movers From Friday
↗
August 23, 2021
Gainers Regencell Bioscience Holdings Limited (NASDAQ: RGC) shares climbed 204.1% to close at $19.16 on Friday. Regencell Bioscience reported partial exercise of underwriter...
Via
Benzinga
22 Stocks Moving in Friday's Pre-Market Session
↗
August 20, 2021
Gainers GeoVax Labs, Inc.. (NASDAQ: GOVX) shares rose 72.1% to $7.40 in pre-market trading after the company announced it presented COVID-19 vaccine data at the European Society...
Via
Benzinga
NLS Pharma Stock Gains After Issuance Of Mazindol Patent
↗
August 19, 2021
NLS Pharmaceutics Ltd (NASDAQ: NLSP) has received a Notice of Allowance from the U.S. Patent and Trademark Office for patent application No. 16/083,131. ...
Via
Benzinga
Topics
Intellectual Property
NLS Pharmaceutics Announces Notice of Allowance for U.S. Patent Application Covering its Proprietary Mazindol Formulation
August 19, 2021
STANS, SWITZERLAND / ACCESSWIRE / August 19, 2021 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage pharmaceutical company focused on the discovery...
From
NLS Pharmaceutics AG
Via
AccessWire
Topics
Intellectual Property
Regulatory Compliance
NLS Pharmaceutics to Participate in the Canaccord Genuity 41st Annual Growth Conference
August 05, 2021
STANS, SWITZERLAND / ACCESSWIRE / August 5, 2021 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP, NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage pharmaceutical company focused on the discovery and...
From
NLS Pharmaceutics AG
Via
AccessWire
NLS Pharmaceutics Announces the Appointment of Eric Konofal, M.D., Ph.D. as Chief Scientific Officer
July 19, 2021
STANS, SWITZERLAND / ACCESSWIRE / July 19, 2021 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW), a Swiss clinical-stage pharmaceutical company focused on the discovery and development of...
From
NLS Pharmaceutics AG
Via
AccessWire
Topics
Intellectual Property
Regulatory Compliance
NLS Pharma Stock Gains As Its Narcolepsy Candidate To Enter Mid-Stage Study Next Month
↗
July 15, 2021
The FDA has accepted NLS Pharmaceutics Ltd's (NASDAQ: NLSP) Investigational New Drug application for Quilience (mazindol extended-release (mazindol ER), the...
Via
Benzinga
NLS Pharmaceutics Announces FDA Acceptance of IND Application to Initiate Clinical Trials with Quilience(R) (mazindol ER) to Treat Narcolepsy
July 15, 2021
Planned Phase 2a clinical trial anticipated to commence in August 2021 STANS, SWITZERLAND / ACCESSWIRE / July 15, 2021 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a...
From
NLS Pharmaceutics AG
Via
AccessWire
Topics
Intellectual Property
Regulatory Compliance
NLS Pharmaceutics to Present at the Access to Giving Virtual Investor Conference on July 15th
July 09, 2021
STANS, SWITZERLAND / ACCESSWIRE / July 9, 2021 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage pharmaceutical company focused on the discovery and...
From
NLS Pharmaceutics AG
Via
AccessWire
50+ Companies to Present at the Access to Giving Virtual Investor Conference on July 13th - 15th, 2021
July 08, 2021
RALEIGH, NC / ACCESSWIRE / July 8, 2021 / Access to Giving - an investor conference themed around investor education and advocacy begins next week, July 13th - 15th, 2021. More than 50 companies are...
From
Access to Giving
Via
AccessWire
35 of the Best Ideas Companies to Present at the Summer Solstice - Best Ideas from the Buy-Side Virtual Investor Conference on June 1-4, 2021
May 27, 2021
RALEIGH, NC / ACCESSWIRE / May 27, 2021 / The Summer Solstice - Best Ideas from the Buy-Side will take place on June 1-4, 2021, where 35 SmallCap, MicroCap and NanoCap public companies will be...
From
MicroCap Rodeo
Via
AccessWire
50+ Companies to Present at the Access to Giving Virtual Investor Conference on July 13th - 15th, 2021
June 23, 2021
RALEIGH, NC / ACCESSWIRE / June 23, 2021 / Access to Giving - an investor conference themed around investor education and advocacy is set for July 13-15, 2021. There will be 50+ companies conducting...
From
Access to Giving
Via
AccessWire
New Study Data Confirms NLS Pharmaceutics' Mazindol Orexin Pathway Activation For Sleeping Disorder
↗
May 18, 2021
NLS Pharmaceutics Ltd (NASDAQ: NLSP) has announced new study data which support the mechanism of action for mazindol, the active compound in the Company's lead...
Via
Benzinga
30 Stocks Moving In Wednesday's Mid-Day Session
↗
April 14, 2021
Gainers Discovery, Inc. (NASDAQ: DISCB) shares climbed 37.3% to $102.99. Grupo Televisa, S.A.B. (NYSE: TV) shares climbed 22.4% to $12.39 after the company reached an agreement...
Via
Benzinga
22 Stocks Moving in Wednesday's Pre-Market Session
↗
April 14, 2021
Gainers Galectin Therapeutics Inc. (NASDAQ: GALT) rose 37.6% to $2.98 in pre-market trading after the company said a paper published in the peer-reviewed Journal for...
Via
Benzinga
50 Biggest Movers From Yesterday
↗
April 14, 2021
Gainers Mackinac Financial Corporation (NASDAQ: MFNC) shares surged 60.7% to close at $21.16 on Tuesday after the company, and Nicolet Bankshares, jointly announced the execution...
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
Next >
